Intrapartum oral azithromycin versus placebo alone or in combination with other antimicrobials on maternal infection in South East Asia.
Patel Archana B AB, Kurhe Kunal K, Bhargav Savita S, Khedikar Vaishali V et al.
In low-resource facilities that routinely use intrapartum prophylactic antimicrobials, the use of multiple antimicrobials could be rationalised by a single oral dose of oral azithromycin. The Azithromycin Prevention in Labor Use Study (A-PLUS), a randomized double-blind, placebo-controlled trial performed across eight sites in seven countries amongst women who planned to deliver vaginally. They were randomly assigned to receive study drug, a single intrapartum 2 gm oral dose of azithromycin or an identical appearing placebo. Data from four South-East Asia sites (Indian sites Nagpur and Belagavi, Pakistan, and Bangladesh) was analyzed to evaluate whether the use of non-study antimicrobials (alone or in-combination) given after randomization through one-day postpartum for any indication (prophylactic or treatment) modified the effect of study drugs on maternal outcomes (maternal infections, antibiotic usage 2-42days postpartum on ambulatory basis or re-hospitalization). The non-study antimicrobials given after randomization through 1-day postpartum was defined by four exposure sub-groups within azithromycin and placebo arm as, Use of: i) No non-study antibiotic; ii) Cephalosporin only; iii) Other non-study non-cephalosporin antibiotics; and iv) Cephalosporin and other non-study non-cephalosporin antibiotics. An intent to treat (ITT) analysis was adopted. Adjusted relative risks and 95% confidence intervals comparing azithromycin with placebo were estimated using Poisson regression models with robust variance estimators that included study site, maternal non-study antimicrobial use, and a treatment-by-non-study antimicrobial use interaction term. All maternal non-study antibiotic subgroups had balanced randomization between azithromycin and placebo. The risk of any maternal infections was reduced when only azithromycin was received versus placebo (RR = 0.75; 95% CI-0.57-0.98) and when group iv antimicrobials were used with azithromycin compared to only group iv antimicrobials (RR = 0.79; 95% CI-0.66-0.95). The use of antibiotics from day2-42 was similar in both arms (azithromycin or placebo) with or without use of other antimicrobials. This secondary analysis found no evidence that non-study antimicrobials use modified the effect of azithromycin on maternal outcomes. This study underscores the importance of considering an easily administrable intrapartum prophylaxis of oral monotherapy in low resource, high risk for infections sites to reduce antimicrobial resistance due to multiple antimicrobial use.